Clinical Trials on Human Immunodeficiency Virus (HIV)

Total 11570 results

American Gene Technologies International Inc.

Enrolling by invitation

An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

HIV

United States
Kirby Institute
The University of New South Wales

Completed

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Human Immunodeficiency Virus (HIV)
Unity Health Toronto
Gilead Sciences; Ryerson University; Maple Leaf Research; AIDS Committee of Toronto and other collaborators

Completed

PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 (PREP-5)

HIV | Human Immunodeficiency Virus

Canada
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Human Immunodeficiency Virus (HIV) Infection

France, Ukraine, United States, Mexico, Romania, South Africa, Peru, Argentina, Puerto Rico, Russian Federation, Guatemala
AbbVie

Completed

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
The Immunobiological Technology Institute (Bio-Manguinhos)...
Conselho Nacional de Desenvolvimento Científico e Tecnológico

Unknown

Validation of Rapid Tests for the Serological Diagnosis of HIV in 9 to 24 Months Old Children

Human Immunodeficiency Virus | Human Immunodeficiency Virus Transmission | Diagnoses, Syndromes, and Conditions

Brazil
ViiV Healthcare
GlaxoSmithKline

Completed

Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

Infection, Human Immunodeficiency Virus | Fracture
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Spain, United Kingdom, Canada, Thailand, Italy, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
EMD Serono

Completed

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

United States, Canada
Abbott

Completed

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

Human Immunodeficiency Virus-Infection

Germany
National Taiwan University Hospital

Recruiting

HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy

Hepatitis C Virus Infection | Hepatitis C Virus Infection, Response to Therapy of | Human Immunodeficiency Virus (HIV) Coinfection

Taiwan
Northwestern University
National Institute of Mental Health (NIMH)

Not yet recruiting

Text Messaging for Human Immunodeficiency Virus (HIV) Testing in Sexual and Gender Minority (SGM) Teens

HIV
Ottawa Heart Institute Research Corporation
Ontario HIV Treatment Network

Completed

The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients

Human Immunodeficiency Virus (HIV) | Cardiovascular Disease (CVD)

Canada
Icahn School of Medicine at Mount Sinai
National Institute on Drug Abuse (NIDA)

Recruiting

Persuasive Health Communication Intervention for HIV/HCV

Human Immunodeficiency Virus (HIV) | Hepatitis C (HCV)

United States
ANRS, Emerging Infectious Diseases

Completed

Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity ("ImmunoCo27")

HIV Infection
Fundacion Clinic per a la Recerca Biomédica

Unknown

Diagnostic of Human Immunodeficiency Virus (HIV) and Other Sexual Transmission Diseases (STD) in High Risk Populations: Men Who Have Sex With Men (MSM) Users of Chemsex (Care_ChemS)

HIV
Queen Mary University of London
Guy's and St Thomas' NHS Foundation Trust; Barts & The London NHS Trust; Royal... and other collaborators

Active, not recruiting

Implementing Long-Acting Novel Antiretrovirals (ILANA)

Human Immunodeficiency Viruses

United Kingdom
Merck Sharp & Dohme LLC

Not yet recruiting

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

HIV | Human Immunodeficiency Virus
Unity Health Toronto

Completed

Fetal HIV Transmission Risk and Duration of Membrane Rupture

HIV | Human Immunodeficiency Virus

Canada
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) (WIP)

HIV-1 Infection
Duke University
National Institute of Nursing Research (NINR)

Completed

Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women

Human Immunodeficiency Virus (HIV) | Self-esteem | Self-efficacy

United States
Hookipa Biotech GmbH

Not yet recruiting

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Human Immunodeficiency Virus (HIV) Infection

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Human Immunodeficiency Virus (HIV)

United States, Spain, South Africa
Janssen-Cilag G.m.b.H

Completed

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)

Human Immunodeficiency Virus (HIV)

Germany
Energex Systems, Inc.

Unknown

Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)

HIV Infections | HIV

United States
Gilead Sciences

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

HIV | Human Immunodeficiency Virus | HIV-1

United States, Puerto Rico
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Completed

Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America

HIV Infection | Malignant Neoplasm | Recurrent Malignant Neoplasm | Human Immunodeficiency Virus 1 Positive

Mexico, Argentina, Brazil
Napo Pharmaceuticals, Inc.

Completed

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Acquired Immunodeficiency Syndrome | HIV/AIDS | Healthy Volunteers | Human Immunodeficiency Virus | HIV Diarrhea

United States
ViiV Healthcare

Available

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Infection, Human Immunodeficiency Virus
GlaxoSmithKline

Completed

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

HIV Infections | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline
University Ghent

Completed

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

HIV Infections | Infection, Human Immunodeficiency Virus

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Expanded Access Study (DEAP)

HIV Infections | Infection, Human Immunodeficiency Virus

France, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
ViiV Healthcare

Completed

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

Relative Bioavailability Study of GSK1265744 Formulations

Infections, Human Immunodeficiency Virus and Hepatitis

United States
ViiV Healthcare
Shionogi

Completed

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Infections, Human Immunodeficiency Virus and Hepatitis

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Infections, Human Immunodeficiency Virus and Hepatitis

Canada
AIDS Arms Inc.
GlaxoSmithKline

Completed

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

HIV Infections | Kidney Failure | Human Immunodeficiency Viruses

United States
Brown University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Active, not recruiting

Game Plan for PrEP

Alcohol; Harmful Use | Human Immunodeficiency Virus Exposure

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ViiV Healthcare
GlaxoSmithKline

Completed

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

HIV Infections | Infection, Human Immunodeficiency Virus

United States
International AIDS Vaccine Initiative
Targeted Genetics Corporation

Completed

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid (TGC14F)

HIV Infections | Human Immunodeficiency Virus Infections

Uganda, South Africa, Zambia
Eunice Kennedy Shriver National Institute of Child...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

HIV Infections | Disease Transmission, Vertical | Vertical Human Immunodeficiency Virus Transmission

United States, South Africa, Argentina, Brazil, Puerto Rico
G & W Laboratories Inc.
Alquest; SMART Biotech Ltd

Completed

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Hepatitis C | Human Immunodeficiency Virus Infection

United States
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
National Cancer Institute (NCI)

Completed

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

Acquired Immunodeficiency Syndrome | HIV Infection

United States
MRC/UVRI and LSHTM Uganda Research Unit
International AIDS Vaccine Initiative

Recruiting

Feasibility of Identifying, Enrolling and Following Acute and Early HIV-1 Infected Individuals. (KILGORIS)

Acute Human Immunodeficiency Virus Type I Infection

Uganda

Clinical Trials on Human Immunodeficiency Virus (HIV)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations